Company	:	Genomic Expression Inc.
Corporate Address	:	100 Cummings Center, Suite 451C,, Beverly, MA 01915
Offering Minimum	:	$15,000.00
Offering Maximum	:	$1,235,000.00
Minimum Investment Amount (per investor)	:	$250.00

Terms

Offering Type	:	Convertible Promissory Notes
Type of Equity Converted Into	:	Non-Voting Common Stock
Conversion Trigger	:	$2,500,000.00
Maturity Date	:	September 18, 2026
Valuation Cap	:	$50,000,000.00
Discount Rate	:	20.0%
Annual Interest Rate	:	8.0%

What is a Convertible Note?

A convertible note offers you the right to receive Non-Voting Common Stock in Genomic Expression Inc.. The amount of Non-Voting Common Stock you will receive in the future will be determined at the next equity round in which the Company raises at least $2,500,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $50,000,000.00 Valuation Cap or if less, then you will receive a 20.0% discount on the price the new investors are paying. You also receive 8.0% interest per year added to your investment. When the maturity date is reached, if the note has not converted then you are entitled to receive Non-Voting Common Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).

*Annual Interest Rate subject to adjustment of 10% bonus for StartEngine shareholders. See 10% Bonus below.

Investment Incentives and Bonuses*

Loyalty Bonus 5% bonus: As you are an Existing Investor in Genomic Expression, you are eligible for additional bonus interest

Time-Based Perks

Early Bird 1: Invest $1,000+ within the first 4 weeks | 2% bonus interest

Early Bird 2: Invest $10,000+ within the first 4 weeks | 5% bonus interest and get invited to a lunch with Gitte Pedersen, CEO of Genomic Expression in New York on Saturday, November 9.

Early Bird 3: Invest $50,000+ within the first 4 weeks | 10% bonus interest and get invited to a lunch with Gitte Pedersen, CEO of Genomic Expression in New York on Saturday, November 9.

Early Bird 4: Invest $100,000+ within 4 weeks | 15% bonus interest and meet for lunch with founders Gitte Pedersen, CEO, and Morten Pedersen, CSO of Genomic Expression in New York or Boston, date to be determined*.

Early Bird 5: Invest $250,000+ within the first 4 weeks | 15% bonus interest and meet for lunch with founders Gitte Pedersen, CEO, and Morten Pedersen, CSO of Genomic Expression in New York or Boston, date to be determined*.

Early Bird 6: Invest $500,000+ within 4 weeks and select our next cancer to validate. Limited to 1. Contingent upon access to biospecimens. Meet founders Gitte Pedersen, CEO, and Morten Pedersen, CSO of Genomic Expression in New York or Boston - Boston lab tour an option, date to be determined**.

Amount-Based Perks

Tier 1 Perk: Invest $1,000+ and receive a 30% discount on your 1st OneRNA® test for breast or ovarian cancer.

Tier 2 Perk: Invest $100,000+ and receive 5% bonus interest and receive 30% discount on 10 OneRNA® tests for breast or ovarian cancer.

Tier 3 Perk: Invest $250,000+ and receive 10% bonus interest and receive 30% discount on 10 OneRNA® tests**. Meet the founders Gitte Pedersen, CEO, and Morten Pedersen, CSO of Genomic Expression in New York or Boston - Boston lab tour an option, date to be determined*.

Tier 4 Perk: Invest $500,000+ and receive 15% bonus interest and receive 30% discount of 10 OneRNA® tests**. Meet founders Gitte Pedersen, CEO, and Morten Pedersen, CSO of Genomic Expression in New York or Boston - Boston lab tour an option, date to be determined**.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.

**All lab testing will require a physician’s order and a signed consent form. Currently only available for breast and ovarian cancer. A biospecimen is required to be sent to our lab in Boston. Expires after 24 months.

The 10% StartEngine Venture Club Bonus

Genomic Expression Inc. will offer 10% additional bonus interest for all investments that are committed by investors who are eligible for the StartEngine Crowdfunding, Inc. Venture Club Bonus.

Eligible StartEngine convertible note holders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 8.8% instead of 8%.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Eligible investors will also receive the Venture Club Bonus and the Loyalty Bonus in addition to aforementioned bonus.

Saving Lives Now, One Cancer Patient at a Time